Faculty, Staff and Student Publications
Language
English
Publication Date
11-2-2025
Journal
Current Oncology
DOI
41294676
PMID
PMC12650995
PMCID
PMC12650995
PubMedCentral® Posted Date
11-2-2025
PubMedCentral® Full Text Version
Post-print
Abstract
KRAS mutations are implicated in approximately 23% of all human malignancies, with particularly high prevalence in pancreatic ductal adenocarcinoma (PDAC) (~92%), colorectal cancer (CRC) (~49%), and non-small cell lung cancer (NSCLC) (~35%). The recent approval of the KRASG12C-specific inhibitors for NSCLC represents a pivotal advancement in KRAS-targeted therapy. Nevertheless, the emergence of intrinsic and acquired resistance to KRAS-targeted therapies poses a significant clinical obstacle to targeting KRAS, which necessitates a deeper understanding of the resistance mechanisms. Recent progress in proteomic studies has enabled comprehensive profiling of the proteomic alterations driven by KRAS mutations, offering valuable insights into the disrupted KRAS interactome, aberrant signaling pathways and dysregulated cellular processes contributing to tumorigenesis. This review discusses current knowledge on proteomic alterations associated with oncogenic KRAS mutations, with particular focus on allele-specific proteome signatures and the roles of post-translational modifications (PTMs) of KRAS in modulating the functional networks. Furthermore, we highlight recent therapeutic advances targeting KRAS variants and discuss emerging resistance mechanisms from a proteomics-informed perspective.
Keywords
Humans, Proteomics, Proto-Oncogene Proteins p21(ras), Neoplasms, Mutation, Molecular Targeted Therapy, KRAS, cancer, proteomics, interactome, post-translational modifications (PTMs), KRAS inhibition
Published Open-Access
yes
Recommended Citation
Ramesh Karki, Ru Chen, and Sheng Pan, "Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches" (2025). Faculty, Staff and Student Publications. 6391.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/6391
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons